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Abstract
Background: Schmallenberg virus (SBV) is a midge borne virus of cattle and sheep. Infection is typically
asymptomatic in adult sheep but fetal infection during pregnancy can result in abortion, stillbirth, neurological
disorders and malformations of variable severity in newborn animals. It was first identified in Germany and the
Netherlands in 2011 and then circulated throughout Europe in 2012 and 2013. Circulation in subsequent years was
low or non-existent until summer and autumn 2016, leading to an increased incidence of deformed newborn
lambs and calves in 2016–17. This study reports SBV circulation in October 2016 within a group of 24 ewes and 13
rams. The ewes were monitored at 3 times points over an 11 week period (September to December 2016).
Results: Most ewes displayed an increase in SBV VNT with antibody titre increases greater in older, previously
exposed ewes. Two ewes had SBV RNA detectable by RT-qPCR, one on 30/09/16 and one on 04/11/16. Of these
ewes, one had detectable serum SBV RNA (indicating viraemia) despite pre-existing antibody. The rams had been
previously vaccinated with a commercial inactivated SBV vaccine, they showed minimal neutralising antibody titres
against SBV 8 months post-vaccination and all displayed increased titre in October 2016.
Conclusion: This data suggests that SBV circulated for a minimum period of 5 weeks in September to October
2016 in central England. Ewes previously exposed to virus showed an enhanced antibody response compared to
naïve animals. Pre-existing antibody titre did not prevent re-infection in at least one animal, implying immunity to
SBV upon natural exposure may not be life-long. In addition, data suggests that immunity provided by killed
adjuvanted SBV vaccines only provides short term protection (< 8 months) from virus.
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Background
Schmallenberg Virus (SBV), an Orthobunyavirus of the
Bunyaviridae family is a recently emerged virus first identi-
fied within cattle in Germany and the Netherlands during
the summer and autumn of 2011, following which SBV
was associated with deformities seen in newborn calves
and lambs [1, 2]. Infection in adult cattle results in mild
disease with clinical signs including pyrexia, decreased milk
production and diarrhoea while it is typically asymptomatic
in adult sheep [3, 4]. Of much greater economic import-
ance is the occurrence of fetal infection which can result in
abortion, stillbirth, neurologic disorders and limb malfor-
mations in newborn animals with variable severity [5]. This
range of clinical signs has been suggested to be the result
of infection at different gestational stages with early infec-
tion causing most severe cases, similar to Akabane virus,
another Orthobunyavirus [6].
In common with other Orthobunyaviruses, SBV is a vec-
tor borne virus spread by Culicoides sp. biting midges;
with midges of the Culicoides obsoletus complex the main
vectors in Europe [7, 8]. These species have a host range
extending over much of Europe. The midge’s lifecycle is
heavily temperature dependent with peaks in numbers of
midges occurring in late summer and very little activity in
winter, with overwintering in livestock housing a major
method of survival in colder periods of the year [9, 10].
Circulation of SBV in Europe continued during 2012
and 2013 with reported cases in 13,846 holdings includ-
ing alpacas, bison, cattle, sheep, goats, deer, buffalo and
moose from 29 European countries [11]. Within the
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United Kingdom (UK) seroprevalences of up to 73%
were reported in the worst affected counties [12]. Fol-
lowing these outbreaks, three commercial SBV vaccines
were made available. These vaccines, based on inacti-
vated, adjuvanted virus proved to be effective in preven-
tion of SBV associated disease upon implementation in
cattle and sheep [13, 14]. In subsequent years few clin-
ical cases of SBV disease were reported, presumably due
to very high seroconversion rates nationally and the
resulting herd immunity to re-infection [15]. Subsequent
vaccine uptake was low due to perceived low risk of in-
fection, with fewer than 14% of sheep holdings in some
regions using it. Thus resulting in a cease in production
of vaccines until recently, when the Zulvac SBV vaccine
(Zoetis UK Limited, Surrey, UK) was reintroduced to the
commercial market [16].
However low levels of virus circulation in 2014–16
(presumably due to the high numbers of susceptible
hosts which seroconverted in the initial outbreak) meant
that animals born in that time frame (a substantial por-
tion of the 2016 UK sheep flock) were naive to the virus
and vulnerable to infection [17]. Recently, SBV was iden-
tified in a large number of animals in the UK, Ireland
and Belgium in late summer/autumn of 2016, confirmed
by both seroconversion and the identification of SBV
RNA positive Culicoides sp with the subsequent appear-
ance in the 2016–17 lambing season of large numbers of
deformed fetuses [18]. It is of particular importance to
note that this time period (August to September) coincides
with the breeding season of sheep (August to December) in
the majority of European production systems.
This study reports an accurate timing of transmission
in a UK sheep flock participating in an artificial insemin-
ation trial. It reports antibody responses and RT-qPCR
virus detection upon natural re-exposure to SBV in two
groups of animals. Thirteen rams that had previously re-
ceived one of the commercial vaccines in June 2014 and
24 ewes from a flock known to have had natural virus
infection in March–April 2013 during the initial out-
break of the virus [19]. This flock had never been vacci-
nated. The 15 older ewes (born 2010–13) had been
previously naturally exposed to the virus, the 9 younger
ewes born in 2014–15, a period of low or no viral circu-
lation in southern England where this flock was located,
were presumed naive to the virus [16].
Results
The rams (7 Abermax and 6 Aberfield) were vaccinated
according to manufacturer’s instructions with a single
dose of Bovilis SBV (MSD animal health) in June 2014 by
the breeder, at 14months of age. Only one of the thirteen
rams had a virus neutralising antibody titre (16) at the
assay minimum detection level for sheep upon blood sam-
pling in April 2015 at 8months post vaccination, this titre
dropped to 4 by December 2015 at 18months post vaccin-
ation (Fig. 1a).
The 24 Exlana ewes were divided into two subgroups,
those born between 2010 and 2013 (N = 15) and there-
fore alive during the previous SBV outbreak and those
born after, between 2014 and 2015 (N = 9). This flock of
ewes had not been vaccinated for SBV. Of 24 ewes, 2 did
not show detectable neutralising antibodies (VNT ≥ 16)
at all time points, 3064 and 3253. These two ewes, from
the older group both showed negative titres at the initial
time point (30/09/16) (Fig. 1b). Nineteen of the 24 dis-
played a rising antibody titre over two subsequent time
points at some stage in the study, the 5 remaining ewes
were all younger ewes born in 2014 and 2015. Thirteen
ewes displayed a 4 fold or greater increase in antibody
titre in paired samples 4 weeks apart, generally accepted
as an indication of recent exposure to a pathogen. The
median antibody titres for both older and younger ewes
were the same at the beginning and end time points of
the study (256 and 512, respectively).
At week 0 and 11 (30/09/16 and 16/12/16, respect-
ively), titres between groups were indistinguishable ran-
ging from 0 to 1024 with the exception of one ewe
(1133) with a titre of 8192 during week 11. At week 5
(04/11/16), ewes born between 2010 and 2013 showed a
larger neutralising antibody response following exposure
to SBV when compared to younger animals. Comparison
of the increase in antibody titres at 04/11/16 (middle
time point) between older and younger ewes by regres-
sion model found a significantly greater rise in titre of
older ewe.
RT-qPCR was carried out on sera from the ewes at
each time point to detect viraemia. One animal at each
time points, 0 and 5 weeks, were RT-qPCR positive for
SBV viraemia (ewes 3253, an old animal born in 2013
with a CT value of 30.87, and 5182, a young animal born
in 2015, with a CT value of 30.20, respectively) (Fig. 2).
Discussion
The presence of virus neutralising antibodies within only
one of thirteen rams 14months post vaccination suggest
that the protection provided by the Bovilis SBV vaccine
(MSD animal health) is indeed short lived and that
animals would require booster doses before annual
breeding. This is shorter than the estimated 12months
assumed following the initial release of the vaccine [20].
Though, as the purpose of the vaccine was specifically to
prevent foetal infection, short term immunisation could
provide protection for animals during pregnancy assum-
ing vaccination occurred at least 3 weeks prior to breed-
ing, with subsequent yearly boosters [21]. We cannot
categorically rule out the possibility of natural exposure
to SBV in these rams, though other studies have shown
that duration of immunity in sheep recovered from wild
Jones et al. BMC Veterinary Research          (2019) 15:426 Page 2 of 6
type virus infection sheep is long lasting (> 16months)
and have indicated that circulation of SBV in the UK and
the Republic of Ireland was at very low levels in 2013–14
and practically non-existent in 2014–15 [16, 22, 23]. We
also cannot exclude the possibility that the vaccine was
not administered correctly, was compromised due to im-
proper storage or specific batch issues. However, detect-
able titres in at least one individual would indicate this
was unlikely. Although, it is important to note that indica-
tions of infection does not translate to indications of dis-
ease, as vaccine may be protective in preventing clinical
disease. Further work is required in determining the clin-
ical presentation of SBV infection in vaccinated animals
following re-infection.
The lack of change in SBV neutralising titres between
February and December 2015 is consistent with other
UK studies indicating that SBV circulation was not
detectable in the UK sheep population in 2015 [24]. In
comparison, the final blood samples taken from these
rams collected in October 2016 showed increases in
antibody titres suggestive of recent exposure therefore
inferring SBV circulation during this time (Fig. 1a). As
the rams were sacrificed at the third blood sampling
time point further blood samples and therefore demon-
stration of a 4 fold increase in antibody titre were not
able to be performed. In comparison, antibody titres
within 13 of 24 ewes showed a 4 fold increase, generally
accepted as an indication of recent exposure to a
pathogen.
The larger neutralising antibody responses seen at
week 5 (04/11/16) in ewes born between 2010 and 2013
when compared to younger animals, found to be signifi-
cant by regression modelling is suggestive of an anam-
nestic response on re-exposure to virus in the older
animals, likely due to previous infection.
The period of viraemia for SBV in sheep is short with
viral RNA detectable starting from days 1 to 6 post in-
fection for a duration of 4 to 5 days and may overlap
with the development of antibody [13, 23, 25]. The exist-
ence of antibody 4 weeks prior to the detection of vir-
aemia in animal 5182 would indicate that in contrast to
the previously published experimental studies in sheep
pre-existing VNT for SBV does not always protect
against natural infection [23]. This discrepancy may be
Fig. 1 Neutralising Antibody Titres for Ewes and Rams over Three Time Points During/Prior to SBV Circulation. Antibody titres from three time
points a Apr 2015, Dec 2015 and Oct 2016 from 13 rams previously vaccinated against SBV and b 30th Sept 2016 (week 0), 4th Nov 2016 (week
5) and 16th Dec 2016 (week 11) from 15 ewes born between the years 2008 and 2013 (blue) and 9 ewes born between 2014 and 2015 (red).
Grey line signifies the minimum detection level for antibodies (16) using this assay
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due to difference in infective dose of virus (uncontrolled
in natural exposure) or differences in virus strain or
sheep responses (perhaps due to breed differences).
Taken together (seroconversion and viraemia) these
data indicate that SBV was circulating in central England
between 29th September 2016 and 27th October 2016.
This is consistent with contemporaneous data from sur-
veillance monitoring of deformed foetuses with circulation
extrapolated from birth dates of affected lambs and calves
in Scotland between October 2016 and January 2017 [26],
and in England and Wales (http://ahvla.defra.gov.uk/vet-
gateway/schmallenberg/index.htm) between August and
December 2017. Of note this is later than the peak in pre-
dicted midge abundance (August to September) in models
of midge number based on historical data sets [9], though
with increasingly warm autumns likely in the future as a
part of climate change this pattern of late autumn viral
circulation of midge borne diseases is likely to persist. This
elongation in circulation past the predicted period places
circulation well within the sheep breeding season (and
vulnerable period of gestation for lambs) in the UK.
The serological data presented here are in contrast to
that in the limited number of previous studies of natural
and vaccine induced immunity in sheep. Previous re-
search has found that following experimental infection,
animals developed protective immunity that was main-
tained for at least 16 months, while similar studies in
naturally infected cattle showed protective immunity for
at least 24 months [27, 28]. The ewes in this study were
sourced from a flock known to have been exposed to
SBV in winter/spring 2013 (Davies and Daly 2015), and
were known not to have been vaccinated. Some of them
had detectable antibody titres in September 2016 (42
months later). From this data we could not identify
whether this immunity was protective but previous ex-
perimental studies have not shown an antibody boost re-
sponse such as that demonstrated here in animals with
protective immunity [13, 14, 23]. It seems likely that
these animals did not gain lifelong protection from SBV
infection from natural infection. It is possible that an-
nual re-exposure to the virus is necessary to maintain
protective immunity, making such long periods of un-
detectable virus circulation, as occurred between 2013
and 2016, a significant problem with the future manage-
ment of SBV outbreaks in Europe. Management is fur-
ther complicated with the unpredictable nature of the
supply of SBV vaccines.
Conclusion
The data presented here provide an accurate circulation
date for SBV in central England over a period between
September 29th and October 27th 2016. This correlates
well with the predicted peak viral circulation extrapo-
lated from numbers of deformed lambs and calves sub-
mitted for diagnostics in the following spring. This adds
further evidence based assessment to the management
recommendation to shift timing of mating until October
to avoid SBV risk. This study indicates that immunity
against SBV following vaccination with a whole virus
inactivated adjuvanted vaccine does not provide long
term protection against the virus and that booster vacci-
nations annually before breeding would be necessary in
sheep if this vaccination strategy is followed. More ser-
iously the study indicates that sheep previously naturally
exposed to the virus may not be fully protected against
it on re-exposure after a substantial time lapse in virus
exposure. Previously exposed animals do however dis-
play an exaggerated antibody response on re-exposure
when compared with naive animals indicative of some
immunological memory. The current study is observa-
tional and therefore cannot definitively answer questions
Fig. 2 Neutralising Antibody Titres of Two Ewes over Three Time
Points for SBV by RT-qPCR. Antibody titres of two ewes over three
time points (week 0, 5 and 11) commencing 29th Sept 2016. Red
asterisk indicates presence of SBV nucleic acid, determined by RT-
qPCR for SBV S fragment
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about protective long term immune responses following
natural exposure, nonetheless it does provide additional
data that can be used for sheep management in a com-
plicated epidemiological situation.
Methods
Blood was taken from 13 rams (7 Abermax and 6 Aberfield)
and 24 ewes (Exlana) participating in an artificial insemin-
ation trial over an 18month and 11week period, respect-
ively. Animals were purchased directly from commercial
flocks with known disease status for SBV. Animals were
kept in field conditions at pasture with shelter. The land
holder where this study was performed, the University of
Nottingham, granted permission through the university’s
ethics process. All procedures carried out were approved by
the UK Home Office under the ‘Animals (Scientific Proce-
dures) Act 1986’ (licence no. PPL 30/3367). Following com-
pletion of the insemination trial animals were humanely
euthanised by captive bolt.
Virus neutralisation tests (VNT) were performed as
previously reported [29]. Sera for each animal at each
time point were repeated in duplicate. Regression mod-
elling of results was carried out using MLwiN multilevel
modelling software.
Extraction of RNA from blood sera was carried out by use
of the QIAamp viral RNA Mini Kit (Qiagen, Manchester,
UK) following the manufacturers recommended protocol.
RNA was eluted with 30 μl nuclease free water and 1 μl used
for synthesis of cDNA using the moloney murine
leukemia virus (M-MLV) reverse transcriptase (RT)
(Promega, Southampton, UK) according to manufac-
turer’s protocol.
Identification and quantification of viral loads within
cDNA from blood sera at time of sampling was carried
out by quantitative polymerase chain reaction (qPCR) as
previously reported [30]. Reactions were performed
using the LightCycler® 480 system (Roche, Pleasanton,
USA). Subsequent analysis was carried out using Light-
Cycler® 480 software.
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